Merck to Present New Data at ASCO 2024 Highlighting Innovations Across Broad Portfolio and Diverse Pipeline
MSD
Pharmaceutical R&D and Manufacturer
Roway, New Jersey, USA,2024Year5Month15Day——MSD (the corporate name of Merck & Co., Inc. in Kenilworth, NJ, USA) announced that the company will present research data involving more than 25 different types of cancer from its portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, from May 31 to June 4, further demonstrating MSD's continued advancement in clinical research.
"At this year's ASCO Annual Meeting, the release of research data from different types of cancers and disease stages highlighted our commitment and efforts to advance innovative solutions with the potential to shape the future of cancer treatment."Senior Vice President of Merck & Co., Inc. Laboratories, Global Clinical Development Lead in OncologyMarjorie GreenPh.D."This year also marks the 10th anniversary of the first approval of pembrolizumab in the United States. Thanks to the tremendous efforts of patients, researchers, and healthcare professionals worldwide, we have witnessed a significant shift in the landscape of cancer treatment."
About Pembrolizumab[1]Important data releases include updated and long-term follow-up data for certain advanced gastric cancer and advanced melanoma, as well as new quality of life and patient-reported outcome data for metastatic bladder cancer and early-stage non-small cell lung cancer.
Will be inASCOThe key data of Pembrolizumab announced at the conference include:
MSD Continues to Build a Broad Portfolio in the Oncology Field, Will Present Data from Its Diverse R&D Pipeline at ASCO, Including Multiple Studies Evaluating Combination with Pembrolizumab, and the Investigational Personalized Neoantigen Therapy (INT) mRNA-4157 (V940) in Collaboration with Moderna.[3]; Anti-TIGIT therapy vibostolimab[4]The investigational compound vibostolimab/pembrolizumab; the investigational TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, previously known as MK-2870/SKB264), co-developed with Kelun-Biotech.[5]; and the HER3-targeted ADC drug patritumab deruxtecan (HER3-DXd) co-developed with Daiichi Sankyo Company[6]etc.
InASCOKey abstracts of the R&D pipeline disclosed at the meeting include:
MSD Investor Activity
MSD will host an investor event on June 3 at 6:00 PM (Central Time) during the ASCO Annual Meeting to share the company's strategy and programs in the field of oncology. The event will take place in Chicago, USA, and will be broadcast online simultaneously. Investors, analysts, media, and the public can access it through this link.LinkVisit Activity.
More will be inASCOKey abstracts released at the meeting include:
Oral Abstract Session
About MSD's Early-Stage Cancer Clinical Program
Early detection and treatment of cancer can help patients achieve a greater chance of long-term survival. Currently, many cancers are considered treatable and potentially curable in the early stages of the disease. Based on the understanding of pembrolizumab's treatment for various advanced cancers, MSD is conducting approximately 25 registrational studies to explore the use of pembrolizumab in treating various early-stage cancers.
Regarding the Strategic Collaboration between Eisai and MSD
In March 2018, Eisai and MSD (MSD is the corporate name of Merck & Co., Inc., located in Rahway, New Jersey, USA) initiated a strategic collaboration through their subsidiaries for the global co-clinical development and commercial promotion of lenvatinib. Under the agreement, both parties will conduct joint clinical development, manufacturing, and commercial promotion of lenvatinib as a monotherapy or in combination with MSD’s PD-1 inhibitor pembrolizumab. Eisai and MSD are currently evaluating the combination of lenvatinib and pembrolizumab across multiple clinical trials involving various cancer types within the LEAP series of clinical programs.
About Astellas,SeagenCollaboration with MSD
Astellas and Seagen, in collaboration with MSD, have signed a clinical cooperation agreement to evaluate the efficacy of Astellas and Seagen's enfortumab vedotin combined with MSD's pembrolizumab in treating adult patients with previously untreated locally advanced or metastatic urothelial cancer. Pfizer completed its acquisition of Seagen on December 14, 2023.
Regarding the Collaboration between Daiichi Sankyo and MSD
In October 2023, Daiichi Sankyo and MSD (MSD is the corporate name of Merck & Co., Inc., located in Rahway, New Jersey, U.S.) reached a global collaboration. Except for Daiichi Sankyo retaining exclusive rights in Japan, the collaboration involves jointly conducting clinical development and commercial promotion of patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd). Daiichi Sankyo will be fully responsible for product manufacturing and supply.
About MSD
At MSD (the corporate name of Merck & Co., Inc. in the United States, located in Rahway, New Jersey), we are united by a shared purpose: harnessing the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We strive to be a top research-intensive biopharmaceutical company — today, we are at the forefront of research, delivering innovative solutions to advance the prevention and treatment of diseases in humans and animals. We have built a diverse and inclusive global workforce, operating responsibly every day to ensure a safe, sustainable, and healthy future for all people and communities. For more information, please visitwww.msd.com, and follow us on Twitter, Facebook, Instagram, YouTube, and LinkedIn.
About MSD China
China is a crucial part of MSD's global growth strategy. MSD’s China headquarters is located in Shanghai, with a research and development center in Beijing and manufacturing facilities in Hangzhou, Ningbo, and Tianjin, integrating R&D, manufacturing, and commercial operations. We are fully committed to providing the people of China with high-quality innovative medicines, vaccines, and services for the benefit of Chinese society. For more information, please visit MSD China's official website or follow MSD China's official social media account on WeChat.
MSD Forward-Looking Statements
MSD's global headquarters is located in Rahway, New Jersey, USA (hereinafter referred to as "the Company"). This press release contains "forward-looking statements" made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The content herein is based on the current views and expectations of the Company’s management and is subject to significant risks and uncertainties. MSD does not guarantee that its investigational products will receive the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties arise, actual results may differ materially from those anticipated in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors (including interest rate and currency fluctuations), the recent global outbreak of the novel coronavirus (COVID-19), the impact of pharmaceutical industry regulations and healthcare policies in the United States and other countries, the global trend toward controlling healthcare costs, technological advancements, new products and patents obtained by competitors, inherent challenges in new product development (including obtaining regulatory approval), MSD's ability to accurately predict future market conditions, difficulties or delays in production, instability in international economic and financial conditions and sovereign risks, reliance on the effectiveness of MSD's patent protection and other innovative products, and the risk of patent litigation and/or regulatory actions against the company.
MSD has no obligation to publicly update any forward-looking statements due to new information, future events, or other reasons. Other factors may cause actual results to materially differ from forward-looking statements; see MSD's 2023 Annual Report on Form 10-K and other documents filed by the company with the U.S. Securities Exchange Commission (available on the U.S. Securities Exchange Commission website).www.sec.gov) for reference.
[1] As of now, the National Medical Products Administration (NMPA) has approved the following indications for pembrolizumab, with other indications yet to be approved:
This indication has been granted conditional approval based on surrogate endpoints, with clinical endpoint data not yet available. Efficacy and safety remain to be further confirmed post-marketing.
[2] Collaboration with Pfizer and Astellas
[3] As of now, mRNA-4157 has not been approved by the NMPA.
[4] As of now, vibostolimab has not been approved by the NMPA.
[5] As of now, sacituzumab tirumotecan has not been approved by the NMPA.
[6] As of now, patritumab deruxtecan (HER3-DXd) has not been approved by the NMPA.
[7] Responsibility of Moderna
[8] Independently Responsible by Kelun-Biotech
[9] Independently Responsible by Kelun-Biotech
[10] Independently Responsible by Kelun Biotech
[11] Supported by Georgetown University, in collaboration with BioXcel Therapeutics, Inc.
[12] Collaboration with Pfizer and Astellas
[13] Independently Responsible by Kelun-Biotech
[14] In collaboration with Eisai; as of now, the NMPA has approved the following indications for lenvatinib, other indications have not been approved yet: